Biotechs are equipping CAR-T cells to destroy B cells — not to treat blood cancers, but to take on multiple sclerosis and a raft of autoimmune disorders
Delivering DNA Aptamers Across the Blood–Brain Barrier Reveals Heterogeneous Decreased ATP in Different Brain Regions of Alzheimer’s Disease Mouse Models
NEW
#ASAP
by
@LuLabUT
Read it here:
Dr. Rostislav Skrabana et al. propose a transient gene expression platform for universal medium-scale production of antibodies and other proteins in Chinese Hamster Ovary (CHO) cells:
Bivalent inhibitors of the BTB E3 ligase KEAP1 enable instant NRF2 activation to suppress acute inflammatory response by Mengchen Lu, Jianai Ji, Qidong You, Zhengyu Jiang, and colleagues at China Pharmaceutical University
New Research: Role of the type 3 cytokines IL-17 and IL-22 in modulating metabolic dysfunction-associated steatotic liver disease
#FrontiersIn
#Immunology
ORIC-533: A Bioavailable Monophosphonic Acid Inhibitor of CD73 for the Treatment of Multiple Myeloma |
Check out our coverage of ORIC Pharmaceuticals’ recent disclosure of their clinical CD73 inhibitor, ORIC-533, at ACS Spring 2024:
Review by Dr. Kar Muthumani et al. explores new methods for monoclonal antibody delivery, including synthetic nucleic acids, and their potential to increase the accessibility and utility of life-saving treatments for several diseases:
In Brief:
@Roche
strikes partnership with neuro-focused biotech
@AscidianTx
over an RNA editing platform. Roche will pay $42M up front and up to $1.8B in milestones and commercial royalties
For readers interested in cancer immunotherapy, this review in the August issue discusses how delivery technologies such as lipid nanoparticles, hydrogels and scaffolds can reduce the clinical barriers for in situ cancer vaccines
A Dual-Selective αvβ6-αvβ1 Inhibitor With Surprising Safety Data
This article highlights why this molecule is currently a big deal in IPF, why the data observed so far is surprising, how it compares to related molecules, and more!
Full Article:
In vivo AAV–SleepingBeauty-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy including CALHM2
@NatureBiotech
@LupengYe
@sidichen